Sophia Genetics, Paragon Genomics Team on SARS-CoV-2 Testing

332
Business people joining hands together for deal

Artificial intelligence-drive health technology company Sophia Genetics, has announced it is extending its partnership with next-generation sequencing (NGS) assay development company Paragon Genomics, to provide a COVID-19 test offering that combines Paragon Genomics’ CleanPlex SARS-CoV-2 NGS panel reagent kit for whole-genome sequencing of the coronavirus with the advanced analytical power of the SOPHiA platform.

“This unique solution provides multiple benefits for patients and the global medical community at large: a significant increase in the throughput of available COVID-19 diagnostic tests by complementing current PCR-based approaches, a higher analytical quality notably linked to higher sensitivity, and the ability to longitudinally track the evolution of the virus over time at a whole-genome level, said Philippe Menu, Sophia Genetics chief medical officer, in a press release. “Viral antigenic drifts over time and around the world will be of paramount importance going forward. This will enable us to accelerate accurate diagnosis capabilities, support global epidemiology efforts as the disease progresses and work with our biopharma partners to accelerate the development of candidate vaccines and anti-viral therapeutic approaches.”

Through Sophia’s global decentralized approach, which now include an installed base of more than 1,000 hospitals worldwide, healthcare institutions worldwide will be able to leverage high quality NGS-based genomic testing in order to scale accurate diagnoses and help address the exponentially growing number of cases.

“The current situation is dramatic and diagnostic capabilities haven’t scaled as we would have hoped. NGS approaches seem to become essential,” said Jurgi Camblong founder and CEO of Sophia. “Given that thousands of hospitals around the world are already equipped with NGS instruments, accurate NGS based tests could be critical to scale and support the increasing need for diagnosis. Such approach will require specific data analytics solutions. Given our current install base with SOPHiA Platform in over 1,000 hospitals worldwide we have taken the decision to temporarily deviate our development efforts from our focus on Hereditary disorders and Oncology and add additional resources to support the medical community addressing the current COVID-19 pandemic.”

This site uses Akismet to reduce spam. Learn how your comment data is processed.